Next
Generation
Solution

for Temporary Mechanical
Circulatory Support

Developing a low-profile, high-flow percutaneous ventricular assist device (pVAD) for high risk coronary intervention and cardiogenic shock.

Clinical Need

Percutaneous ventricular assist devices (pVADs) are placed to provide temporary mechanical support, assisting the native pumping action of the heart and enabling patients to undergo necessary interventional procedures.

Patients with coronary artery disease (CAD) often require interventions such as angioplasty or stenting. Many patients with advanced disease or complicating comorbidities are not able to undergo percutaneous coronary interventional (PCI) procedures without the use of temporary support from a pVAD.

120K High-risk Percutaneous Coronary Procedures in the US Each Year

Patients that have a severe heart attack can suffer from cardiogenic shock (CS). During CS, a patient’s heart is too weak to adequately pump blood to vital organs and a pVAD may be required.

50% Mortality Rate

Solution

Next Generation Solution for Temporary Mechanical Circulatory Support

Icon S

High-flow from a low-profile catheter pump designed to minimize vascular complications

Aiming to provide real-time, accurate monitoring of pump performance and location

Robust platform intended to address both high-risk PCI and cardiogenic shock patients

Company

Supira Medical, Inc. is a portfolio company of Shifamed, LLC., a highly-specialized medical innovation hub focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives.

Leadership Team

Nitin Salunke
Nitin Salunke

President & CEO

David Voris
David Voris

Chief Financial Officer

Janine Robinson
Janine Robinson

Vice President, R&D

Adnan Merchant

Vice President,
Systems Engineering

Katie Arnold
Katie Arnold

Marketing Strategy Consultant

Amr Salahieh
Amr Salahieh

Chairman of the Board

Mariam Maghribi
Mariam Maghribi

Chief Business Officer, Shifamed

Debbie White
Debbie White

Sr. VP, HR & Administration

Robert Edesess

Vice President, Intellectual Property

Laura Minarsch
Laura Minarsch

Clinical Consultant

Nitin Salunke
Nitin Salunke

President & CEO

David Voris
David Voris

Chief Financial Officer

Janine Robinson
Janine Robinson

Vice President, R&D

Adnan Merchant
Adnan Merchant

Vice President,
Systems Engineering

Katie Arnold
Katie Arnold

Marketing Strategy Consultant

Amr Salahieh
Amr Salahieh

Chairman of the Board

Mariam Maghribi
Mariam Maghribi

Chief Business Officer, Shifamed

Debbie White
Debbie White

Sr. VP, HR & Administration

Robert Edesess

Vice President, Intellectual Property

Laura Minarsch
Laura Minarsch

Clinical Consultant

Nitin Salunke
Nitin Salunke

President & CEO

David Voris
David Voris

Chief Financial Officer

Janine Robinson
Janine Robinson

Vice President, R&D

Adnan Merchant
Adnan Merchant

Vice President,
Systems Engineering

Katie Arnold
Katie Arnold

Marketing Strategy Consultant

Amr Salahieh
Amr Salahieh

Chairman of the Board

Mariam Maghribi
Mariam Maghribi

Chief Business Officer, Shifamed

Debbie White
Debbie White

Sr. VP, HR & Administration

Robert Edesess

Vice President, Intellectual Property

Laura Minarsch
Laura Minarsch

Clinical Consultant

Interested in joining the team?

View open positions with Supira Medical and Shifamed’s portfolio companies.

View Openings
Note: Principals only. No third-party referrals will be accepted without prior approval by Shifamed. As a general practice, Shifamed does not accept unsolicited resumes or placement information from any individual or agency that supplies candidates for a fee.

News

Supira Medical, A Shifamed Portfolio Company, Closes $35M in Series B Financing

Company Appoints Seasoned Medtech Executive as President and CEO

CAMPBELL, Calif., March 5, 2020 – Supira Medical, formed by Shifamed as part of its medical innovation hub, announced today the closing of $35M in Series B financing. Officially closed on February 25, the financing was led by Cormorant Asset Management with participation from The Capital Partnership (TCP), 415 CAPITAL, AMED Ventures and Shifamed Angels. The funds will be used to advance product development and clinical efforts for the company’s next generation percutaneous ventricular assist device (pVAD). Additionally, the company announced the appointment of seasoned medical device executive, Dr. Nitin Salunke, as President and Chief Executive Officer.

Read More

Contact

Supira Medical
590 Division Street
Campbell, CA 95008
info@supiramedical.com